Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
12.65
+0.23 (1.85%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 35 or 116.67% compared to the previous year.
Employees
65
Change (1Y)
35
Growth (1Y)
116.67%
Revenue / Employee
n/a
Profits / Employee
-$2,300,846
Market Cap
763.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
SYRE News
- 15 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 23 days ago - Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PRNewsWire
- 6 weeks ago - Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
- 7 weeks ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PRNewsWire
- 2 months ago - Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation - PRNewsWire
- 3 months ago - Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PRNewsWire
- 4 months ago - Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PRNewsWire